JP2013518110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518110A5 JP2013518110A5 JP2012551232A JP2012551232A JP2013518110A5 JP 2013518110 A5 JP2013518110 A5 JP 2013518110A5 JP 2012551232 A JP2012551232 A JP 2012551232A JP 2012551232 A JP2012551232 A JP 2012551232A JP 2013518110 A5 JP2013518110 A5 JP 2013518110A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- mono
- substituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 174
- 125000005843 halogen group Chemical group 0.000 claims 114
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 67
- -1 or R 13 and R 14 Chemical compound 0.000 claims 58
- 125000004093 cyano group Chemical group *C#N 0.000 claims 42
- 125000001424 substituent group Chemical group 0.000 claims 39
- 125000003118 aryl group Chemical group 0.000 claims 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 208000002193 Pain Diseases 0.000 claims 20
- 239000003940 fatty acid amidase inhibitor Substances 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 229910052799 carbon Inorganic materials 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 238000001356 surgical procedure Methods 0.000 claims 9
- 208000004296 neuralgia Diseases 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 208000005171 Dysmenorrhea Diseases 0.000 claims 6
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 6
- 208000004454 Hyperalgesia Diseases 0.000 claims 6
- 208000019695 Migraine disease Diseases 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 206010027599 migraine Diseases 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims 6
- 125000000335 thiazolyl group Chemical group 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 208000030814 Eating disease Diseases 0.000 claims 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 5
- 230000036506 anxiety Effects 0.000 claims 5
- 235000014632 disordered eating Nutrition 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 208000014674 injury Diseases 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 4
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 206010047700 Vomiting Diseases 0.000 claims 4
- 208000005298 acute pain Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000003492 excitotoxic effect Effects 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 208000019116 sleep disease Diseases 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 208000008035 Back Pain Diseases 0.000 claims 3
- 208000000094 Chronic Pain Diseases 0.000 claims 3
- 206010019233 Headaches Diseases 0.000 claims 3
- 208000035154 Hyperesthesia Diseases 0.000 claims 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000004550 Postoperative Pain Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000003187 abdominal effect Effects 0.000 claims 3
- 206010053552 allodynia Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 231100000869 headache Toxicity 0.000 claims 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000004371 toothache Diseases 0.000 claims 3
- 208000009935 visceral pain Diseases 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 206010028813 Nausea Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101710138657 Neurotoxin Proteins 0.000 claims 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000004406 elevated intraocular pressure Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 231100000318 excitotoxic Toxicity 0.000 claims 2
- 231100000063 excitotoxicity Toxicity 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 235000020932 food allergy Nutrition 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000008693 nausea Effects 0.000 claims 2
- 239000002581 neurotoxin Substances 0.000 claims 2
- 231100000618 neurotoxin Toxicity 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000011514 reflex Effects 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 201000009881 secretory diarrhea Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- 206010003497 Asphyxia Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 claims 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 206010021333 Ileus paralytic Diseases 0.000 claims 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 claims 1
- 208000001126 Keratosis Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000003243 intestinal obstruction Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 230000001769 paralizing effect Effects 0.000 claims 1
- 201000007620 paralytic ileus Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29908710P | 2010-01-28 | 2010-01-28 | |
| US61/299,087 | 2010-01-28 | ||
| PCT/US2011/022412 WO2011094209A1 (en) | 2010-01-28 | 2011-01-25 | Pharmaceutical compositions for the treatment of pain and other indicatons |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013518110A JP2013518110A (ja) | 2013-05-20 |
| JP2013518110A5 true JP2013518110A5 (enExample) | 2014-03-13 |
Family
ID=44319717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551232A Withdrawn JP2013518110A (ja) | 2010-01-28 | 2011-01-25 | 疼痛および他の適応症の治療用の医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130030000A1 (enExample) |
| EP (1) | EP2528603A4 (enExample) |
| JP (1) | JP2013518110A (enExample) |
| KR (1) | KR20120123691A (enExample) |
| CN (1) | CN102858338A (enExample) |
| AU (1) | AU2011209754A1 (enExample) |
| BR (1) | BR112012018913A2 (enExample) |
| CA (1) | CA2786888A1 (enExample) |
| MX (1) | MX2012008801A (enExample) |
| RU (1) | RU2012136624A (enExample) |
| WO (1) | WO2011094209A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5698666B2 (ja) * | 2008-08-04 | 2015-04-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｆａａｈの阻害剤として有用なオキサゾール誘導体 |
| JP2013523814A (ja) * | 2010-04-08 | 2013-06-17 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｆａａｈの調節薬として有用なオキサゾール誘導体 |
| EP2560655B1 (en) | 2010-04-21 | 2016-08-24 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| EP2799071B1 (en) | 2010-06-16 | 2018-10-17 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast for the treatment of influenza and common cold |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| JP2016512262A (ja) | 2013-03-13 | 2016-04-25 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 血管炎の処置におけるレボセチリジン及びモンテルカストの使用 |
| KR20150135339A (ko) * | 2013-03-13 | 2015-12-02 | 인플래머토리 리스폰스 리서치, 아이엔씨. | 레보세티리진 및 몬테루카스트의 외상성 손상의 치료 용도 |
| ES2745041T3 (es) | 2013-03-13 | 2020-02-27 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios |
| BR112016008378B1 (pt) | 2013-10-14 | 2022-11-08 | Eisai R&D Management Co., Ltd | Compostos de quinolina seletivamente substituídos ou sal dos mesmos, e composição farmacêutica contendo os ditos compostos |
| AU2014334554B2 (en) | 2013-10-14 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| TR201909447T4 (tr) * | 2013-12-04 | 2019-07-22 | Galmed Res & Development Ltd | Aramkol tuzları. |
| WO2016036588A1 (en) * | 2014-09-03 | 2016-03-10 | Merck Sharp & Dohme Corp. | Pharmaceutical suspensions containing etoricoxib |
| WO2016044095A1 (en) | 2014-09-15 | 2016-03-24 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| EP4424683A3 (en) * | 2017-03-13 | 2024-11-06 | Lundbeck La Jolla Research Center, Inc. | Dual magl and faah inhibitors |
| EP3649128A1 (en) | 2017-07-07 | 2020-05-13 | Syngenta Participations AG | Pesticidally active heterocyclic derivatives with sulfur containing substituents |
| KR102257685B1 (ko) | 2018-09-20 | 2021-05-31 | 성균관대학교산학협력단 | Cox-2 억제제를 유효성분으로 포함하는 소염진통 예방 또는 치료용 정제 조성물 |
| CN110156710B (zh) * | 2019-04-30 | 2022-10-28 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种多取代噁唑类化合物的制备方法 |
| JP7464955B2 (ja) | 2020-02-27 | 2024-04-10 | 国立大学法人千葉大学 | ヨードオキサゾール化合物の製造方法、オキサゾール化合物の製造方法 |
| EP4153178A4 (en) * | 2020-05-19 | 2024-06-05 | Irr, Inc. | LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF SEPSIS AND SYMPTOMS THEREOF |
| CA3220526A1 (en) * | 2021-05-28 | 2022-12-01 | Mark J. Rosenfeld | Methods for the treatment of post-traumatic stress disorder and traumatic brain injury with cannabinoids |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60327640D1 (enExample) * | 2002-10-08 | 2009-06-25 | Scripps Research Inst | |
| DK1836179T3 (en) * | 2004-12-30 | 2015-05-26 | Janssen Pharmaceutica Nv | PIPERIDINE AND PIPERAZINE-1-CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FAT ACID AMIDE HYDRALASE (FAAH) FOR THE TREATMENT OF ANCIENT, PAIN AND OTHER CONDITIONS |
| US7790720B2 (en) * | 2005-03-31 | 2010-09-07 | Ucb Pharma, S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
| WO2008147553A1 (en) * | 2007-05-25 | 2008-12-04 | The Scripps Research Institute | Tetracyclic inhibitors of fatty acid amide hydrolase |
| CA2727245A1 (en) * | 2008-06-11 | 2009-12-17 | Merck Sharp & Dohme Corp. | Imidazole derivatives useful as inhibitors of faah |
| CA2727242A1 (en) * | 2008-06-11 | 2009-12-17 | Merck Sharp & Dohme Corp. | Pyrazole derivatives useful as inhibitors of faah |
| JP5698666B2 (ja) * | 2008-08-04 | 2015-04-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｆａａｈの阻害剤として有用なオキサゾール誘導体 |
-
2011
- 2011-01-25 MX MX2012008801A patent/MX2012008801A/es not_active Application Discontinuation
- 2011-01-25 EP EP11737514.7A patent/EP2528603A4/en not_active Withdrawn
- 2011-01-25 JP JP2012551232A patent/JP2013518110A/ja not_active Withdrawn
- 2011-01-25 KR KR1020127022379A patent/KR20120123691A/ko not_active Withdrawn
- 2011-01-25 CA CA2786888A patent/CA2786888A1/en not_active Abandoned
- 2011-01-25 US US13/574,303 patent/US20130030000A1/en not_active Abandoned
- 2011-01-25 CN CN2011800171616A patent/CN102858338A/zh active Pending
- 2011-01-25 AU AU2011209754A patent/AU2011209754A1/en not_active Abandoned
- 2011-01-25 RU RU2012136624/15A patent/RU2012136624A/ru not_active Application Discontinuation
- 2011-01-25 BR BR112012018913A patent/BR112012018913A2/pt not_active IP Right Cessation
- 2011-01-25 WO PCT/US2011/022412 patent/WO2011094209A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518110A5 (enExample) | ||
| RU2012136624A (ru) | Фармацевтические композиции для лечения боли и других показаний | |
| TWI712595B (zh) | 三環性螺化合物 | |
| JP5941598B2 (ja) | ５員ヘテロアリールおよびそれらの抗ウイルス剤としての使用 | |
| JP2012505891A5 (enExample) | ||
| JP6323629B1 (ja) | Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ | |
| JP6859323B2 (ja) | カルボキシ置換（ヘテロ）芳香環誘導体並びにその調製方法及び使用 | |
| JP2011510068A5 (enExample) | ||
| CN107074840B (zh) | 用于治疗炎性疾病和过度增殖性疾病的具有作为cPLA2抑制剂的活性的2-氧代噻唑化合物 | |
| JP2013544804A5 (enExample) | ||
| JP2010516701A5 (enExample) | ||
| JP2008540661A5 (enExample) | ||
| CN113784970A (zh) | Erk抑制剂及其应用 | |
| RU2007134456A (ru) | Индольные производные 1-уксусной кислоты, обладающие антагонистической активностью по отношению к pgd-d2 | |
| JP2007515489A5 (enExample) | ||
| JP2010516700A5 (enExample) | ||
| JP2014530243A5 (ja) | Ａｒｒｙ−３８０の多形体、選択的ｅｒｂｂ２（ｈｅｒ２）阻害剤、およびそれらを含有する薬学的組成物 | |
| JP2007517006A5 (enExample) | ||
| RU2010116293A (ru) | Алкилтиопиримидины в качестве антагонистов crth2 | |
| JP2007517007A5 (enExample) | ||
| JP2013525490A5 (enExample) | ||
| JP2017537957A (ja) | 置換されたピリジル−シクロアルキル−カルボン酸類、それらを含む組成物およびそれらの医学的使用 | |
| CN114423762A (zh) | 大环类衍生物及其制备方法和用途 | |
| CA2936707A1 (en) | Diaminoguanidine derivatives and application thereof in preparation of animal growth promoters used in feed | |
| CN110431144A (zh) | 氰基取代的杂芳基并嘧啶酮类衍生物及其制备方法和用途 |